- Which of the following is the most appropriate perioperative management of his dual antiplatelet therapy?
Answer: Continue aspirin through the perioperative period and hold clopidogrel for 5 days before surgery.
When managing antiplatelet therapy in patients requiring surgery, you must balance thrombotic risk against bleeding risk. This patient presents a classic dilemma: recent stroke requiring dual antiplatelet therapy (DAPT) versus urgent cancer surgery with bleeding concerns.
The correct approach is D - continue aspirin and hold clopidogrel for 5 days. Here's why: aspirin provides essential cardiovascular protection with relatively modest bleeding risk, while clopidogrel (a P2Y12 inhibitor) significantly increases surgical bleeding and can be safely interrupted. Clopidogrel's antiplatelet effects last 5-7 days after discontinuation, so stopping it 5 days preoperatively allows platelet function recovery while maintaining some dual protection until surgery.
A is wrong because stopping both agents creates unnecessary thrombotic risk, especially given his recent stroke. Seven days may be excessive for aspirin cessation. B is incorrect because anticoagulation with LMWH doesn't replicate antiplatelet effects and actually increases bleeding risk when combined with surgery. Bridging is typically used for anticoagulation, not antiplatelet therapy. C is inappropriate because delaying cancer surgery for 6 months allows tumor progression and metastasis - the bleeding risk from surgery generally outweighs the thrombotic risk of temporarily modifying DAPT.
Key strategy: In perioperative DAPT management, remember that aspirin is usually continued (lower bleeding risk, high cardiovascular benefit), while P2Y12 inhibitors like clopidogrel are held 5-7 days before major surgery. Cancer surgery timing takes priority over completing full DAPT duration, but some antiplatelet protection should be maintained.
- Which of the following is the most appropriate next step in management?
Answer: Refer for botulinum toxin injections to the affected muscles.
This patient has focal spasticity that is causing pain and functional impairment. For this indication, botulinum toxin injection into the affected muscles is a first-line treatment. It works by inhibiting acetylcholine release at the neuromuscular junction, causing targeted muscle relaxation. Oral medications like baclofen or diazepam can be used but often cause systemic side effects such as sedation and generalized weakness before achieving a therapeutic effect on focal spasticity. While physical therapy is essential, it is not sufficient for severe cases.
- What is the most appropriate recommendation regarding seizure prophylaxis for this patient?
Answer: Prophylactic anti-epileptic drugs are not recommended and should not be started.
Current guidelines from the American Heart Association/American Stroke Association do not recommend the prophylactic use of anti-epileptic drugs (AEDs) after an ischemic stroke. While post-stroke seizures can occur, prophylactic AEDs have not been shown to prevent their first occurrence or the development of post-stroke epilepsy, and they expose the patient to unnecessary side effects. AEDs should only be initiated if a patient has a clinical seizure.
- In addition to continuing his current medical therapy, which of the following is the most appropriate next step to guide long-term secondary prevention?
Answer: Prescribe a 30-day ambulatory cardiac event monitor.
Up to 30% of ischemic strokes are cryptogenic. Paroxysmal atrial fibrillation (AF) is a common cause that is often missed on short-term monitoring. Guidelines recommend prolonged ambulatory cardiac monitoring (e.g., for 30 days) for patients with cryptogenic stroke to increase the diagnostic yield for AF. A diagnosis of AF would fundamentally change management from antiplatelet therapy to anticoagulation.
- Which of the following is the most appropriate next step in her management?
Answer: Increase the amlodipine dose or add a second antihypertensive agent.
For secondary stroke prevention, current AHA/ASA guidelines recommend a target blood pressure of <130/80 mmHg. This patient's blood pressure is above this goal. Therefore, her antihypertensive regimen should be intensified. This can be achieved by increasing the dose of her current medication (amlodipine) or by adding a second agent, such as a thiazide diuretic or an ACE inhibitor/ARB.
- In addition to aggressive management of vascular risk factors, which of the following is the most appropriate initial intervention for his cognitive deficits?
Answer: Referral for cognitive rehabilitation and occupational therapy.
The patient is exhibiting symptoms of post-stroke cognitive impairment, consistent with vascular dementia. While aggressive management of vascular risk factors (hypertension, diabetes, dyslipidemia) is the cornerstone of preventing progression, symptomatic management is also important. The most appropriate initial intervention is non-pharmacologic. Cognitive rehabilitation and occupational therapy can help the patient develop compensatory strategies to improve functional independence and safety. While medications like donepezil have a modest and sometimes controversial role, rehabilitation is a key first step.
- Which of the following is the most appropriate initial pharmacologic treatment for this patient's condition?
Answer: Sertraline
This patient is exhibiting classic symptoms of post-stroke depression, a common and serious complication. Selective serotonin reuptake inhibitors (SSRIs) are the first-line pharmacologic treatment. Sertraline is a frequently used agent due to its favorable side-effect profile in the elderly and fewer drug-drug interactions compared to other antidepressants. Amitriptyline has significant anticholinergic and cardiac side effects. Lorazepam can worsen depression and cause sedation. Methylphenidate is used for apathy, not major depression.
- Which of the following dietary patterns has the strongest evidence for reducing the risk of recurrent stroke?
Answer: A Mediterranean-style diet with an emphasis on sodium restriction.
When you encounter stroke prevention questions, focus on evidence-based dietary interventions that address multiple cardiovascular risk factors simultaneously, especially in patients with metabolic syndrome features like this obese, hypertensive patient.
The Mediterranean diet with sodium restriction (D) has the strongest evidence for stroke prevention. Large randomized controlled trials, particularly PREDIMED, demonstrated that a Mediterranean dietary pattern rich in olive oil, nuts, fruits, vegetables, whole grains, and fish reduces stroke risk by approximately 30%. The addition of sodium restriction is crucial for this hypertensive patient, as high sodium intake directly contributes to elevated blood pressure, a major modifiable stroke risk factor. This diet addresses multiple pathways: reducing inflammation, improving endothelial function, lowering blood pressure, and optimizing lipid profiles.
Option A is incorrect because ketogenic diets lack robust evidence for stroke prevention and may actually increase cardiovascular risk in some patients due to potential increases in LDL cholesterol and limited long-term safety data.
Option B fails because focusing solely on dietary cholesterol restriction is outdated and overly narrow. Dietary cholesterol has minimal impact on blood cholesterol for most people, and this approach ignores other important risk factors.
Option C is wrong because high-protein, low-fat diets emphasizing lean meats don't address the comprehensive nutritional needs for stroke prevention and may lack the anti-inflammatory compounds found in plant-rich diets.
For USMLE Step 3, remember that evidence-based medicine drives recommendations. When asked about dietary interventions for cardiovascular disease prevention, Mediterranean diet consistently shows the strongest clinical trial evidence across multiple outcomes.
- Which of the following is the most critical intervention for the secondary prevention of hemorrhage in this patient?
Answer: Intensive blood pressure reduction with a target systolic pressure of less than 130 mmHg.
Hypertension is the single most important modifiable risk factor for spontaneous deep intracerebral hemorrhage (ICH). The location in the basal ganglia is classic for a hypertensive bleed. Aggressive blood pressure control is the cornerstone of secondary prevention. The ATACH-2 and INTERACT2 trials support a target systolic blood pressure of <130-140 mmHg. Initiating aspirin is contraindicated as it would increase the risk of recurrent hemorrhage. While alcohol is a risk factor, BP control is paramount. A vascular malformation is less likely in this location and age group.
- Which of the following is the most appropriate long-term management plan for his secondary stroke prevention?
Answer: Treat H. pylori, start a proton pump inhibitor, and resume aspirin 81 mg daily.
When you encounter a patient requiring both secondary stroke prevention and treatment for a bleeding peptic ulcer, you're balancing two competing risks: thrombotic events versus bleeding complications. The key is understanding that antithrombotic therapy remains essential for stroke prevention, but the bleeding risk can be mitigated.
This patient needs continued antiplatelet therapy for secondary stroke prevention after his lacunar stroke. The bleeding duodenal ulcer was likely caused by aspirin combined with H. pylori infection. The solution isn't to abandon stroke prevention, but to address the underlying causes of bleeding while maintaining antithrombotic protection.
Option D is correct because it treats H. pylori (eliminating a major ulcer risk factor), adds a proton pump inhibitor (reducing gastric acid and ulcer recurrence), and resumes the necessary aspirin for stroke prevention. This approach addresses both conditions appropriately.
Option A is dangerous because permanently stopping antithrombotic therapy leaves the patient unprotected against recurrent stroke, which poses a greater long-term risk than managed bleeding.
Option B substitutes warfarin unnecessarily. Warfarin isn't superior to aspirin for lacunar stroke prevention and actually carries higher bleeding risk, making this substitution counterproductive.
Option C switches to clopidogrel, which offers no proven advantage over aspirin for this indication and is more expensive. While treating H. pylori is appropriate, the antiplatelet switch isn't warranted.
Remember: In secondary stroke prevention, don't let bleeding complications derail necessary antithrombotic therapy. Instead, optimize the patient's condition to safely continue the therapy they need.
- Which of the following is the most appropriate next step in managing his antiplatelet therapy?
Answer: Continue both aspirin and clopidogrel for a total of 90 days, then continue aspirin monotherapy.
For patients with a minor ischemic stroke (NIHSS ≤3) or high-risk TIA, dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is recommended for a short duration to reduce the risk of recurrent stroke. Evidence from the CHANCE and POINT trials supports continuing DAPT for 21 to 90 days. After this period, DAPT should be discontinued and single antiplatelet therapy (e.g., aspirin) should be continued long-term to minimize bleeding risk.
- Which of the following is the most appropriate initial medication for this patient's pain?
Answer: Amitriptyline
This patient's symptoms are classic for central post-stroke pain (CPSP), a neuropathic pain syndrome resulting from a lesion in the central nervous system, commonly the thalamus. First-line treatments for CPSP include tricyclic antidepressants (like amitriptyline) or anticonvulsants (like gabapentin or pregabalin). Opioids, NSAIDs, and acetaminophen are generally not effective for this type of pain.
- Which of the following is the most appropriate long-term management strategy for this patient?
Answer: PFO closure combined with antiplatelet therapy.
Multiple randomized controlled trials (e.g., RESPECT, CLOSE) have demonstrated that in patients aged 18-60 with a cryptogenic stroke attributed to a PFO, percutaneous PFO closure combined with antiplatelet therapy is superior to medical therapy (either antiplatelet or anticoagulant) alone in preventing recurrent stroke. Given this patient's age and clinical presentation, PFO closure is the recommended intervention.
- Which of the following antithrombotic regimens is the most appropriate initial therapy for this patient?
Answer: Aspirin 81 mg and clopidogrel 75 mg daily for 90 days.
This patient has symptomatic intracranial atherosclerotic disease (ICAD). The SAMMPRIS trial demonstrated that aggressive medical management is superior to stenting for high-grade symptomatic ICAD. The medical management arm in this trial included dual antiplatelet therapy with aspirin and clopidogrel for 90 days, followed by aspirin monotherapy, along with high-intensity statin therapy and strict blood pressure control. This has become the standard of care.
- In addition to optimal medical therapy with an antiplatelet, statin, and antihypertensive, which of the following interventions is most appropriate?
Answer: Referral for carotid endarterectomy (CEA).
This patient has high-grade (70-99%) symptomatic carotid stenosis, with the TIA localizing to the affected artery. For such patients, carotid endarterectomy (CEA) in addition to optimal medical therapy has been shown to significantly reduce the risk of subsequent stroke. Carotid artery stenting (CAS) is an alternative, but in patients over age 70, CEA is generally preferred due to a lower periprocedural risk of stroke compared to CAS.
- Which of the following is the most appropriate recommendation regarding his return to driving?
Answer: He should be advised not to drive commercially and will likely require a formal driving assessment for personal driving.
A homonymous hemianopia is a significant visual field defect that severely impairs the ability to drive safely. It is an absolute contraindication to commercial driving in most jurisdictions. For personal driving, it represents a major safety risk, and regulations often preclude licensure. At a minimum, a formal on-road driving evaluation by a specialist is required, but it is unlikely he would be deemed safe. Advising him not to drive commercially is essential for public safety.
- Based on these results, which of the following is the most accurate conclusion?
Answer: Drug Y is more effective than clopidogrel in preventing recurrent stroke but is associated with a higher risk of major bleeding.
The results show that Drug Y reduced the risk of the primary outcome (recurrent stroke) by 31% compared to clopidogrel (HR 0.69). Since the 95% CI (0.55-0.87) does not cross 1.0 and the P value is <0.05, this result is statistically significant. For major bleeding, the risk was 94% higher with Drug Y (HR 1.94). Since this 95% CI (1.35-2.78) also does not cross 1.0 and the P value is <0.05, this increased risk is also statistically significant. Therefore, Drug Y is more effective but less safe.
- Which of the following is the most appropriate change to her medication regimen for secondary stroke prevention?
Answer: Discontinue aspirin and initiate apixaban.
This patient experienced an ischemic stroke in the setting of atrial fibrillation, indicating a cardioembolic source. For secondary stroke prevention in patients with atrial fibrillation, oral anticoagulation is markedly superior to antiplatelet therapy. A direct oral anticoagulant (DOAC) like apixaban is preferred over warfarin due to a better safety profile and ease of use. Aspirin should be discontinued when an anticoagulant is started for this indication to minimize bleeding risk, unless there is another compelling reason for it (e.g., recent coronary stent).
- Which of the following is the most appropriate modification to his antithrombotic regimen?
Answer: Discontinue aspirin and initiate warfarin.
The presence of a left ventricular (LV) thrombus is a high-risk source for systemic embolism, including stroke. Full anticoagulation is indicated to treat the thrombus and prevent further events. Warfarin is the standard of care for LV thrombus, as the efficacy of direct oral anticoagulants (DOACs) in this setting is not well established. Aspirin should be discontinued when initiating warfarin for this indication to reduce the risk of bleeding.
- Which of the following is the most appropriate next step in the management of her dyslipidemia?
Answer: Add ezetimibe 10 mg daily to her current regimen.
Current guidelines recommend high-intensity statin therapy for all patients with ischemic stroke of atherosclerotic origin. The goal is an LDL cholesterol level of <70 mg/dL. This patient is on a maximum dose of a high-intensity statin, but her LDL remains above the goal. The next step is to add a non-statin agent, such as ezetimibe, which has been shown in the IMPROVE-IT trial to provide additional cardiovascular risk reduction when added to a statin.
